FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation By Ogkologos - October 30, 2025 284 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR COVID-19: “It could take months to build research up again” July 1, 2020 Cholesterol Drug May Help Protect the Heart during Chemotherapy for Lymphoma September 8, 2023 Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent... November 24, 2025 FDA Approves New Dosing Regimen for Cetuximab April 13, 2021 Load more HOT NEWS Immunotherapy approved for some people with advanced melanoma in England Mutation Screening Could Reveal Whether Hormone Treatment Will Work for Breast... EMA Recommends Extension of Indications for Nivolumab and Ipilimumab A Combination of Atezolizumab and Enzalutamide Does Not Improve Overall Survival...
